Overview
Overview
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide (9 amino acids) first isolated from rabbit brain tissue and studied for its effects on sleep architecture and stress modulation[1][2]. Research indicates DSIP may promote delta-wave (slow-wave) sleep, modulate cortisol and ACTH levels, and exhibit stress-protective properties[3][4]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements. Recon
- Category
- Cognitive
- Routes
- subcutaneous
Mechanism
DSIP
Mechanism of action
Mechanism of action
DSIP is a small naturally occurring nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of about 849 daltons. Its name comes from the early observation that infusion produced delta-wave (slow-wave) EEG activity in rabbits. Despite decades of work, the precise receptor and mechanism are still not fully established. Reviews describe possible interactions with NMDA receptors, alpha-adrenergic signaling, opioid receptors, and the hypothalamic-pituitary-adrenal axis. DSIP-like material has been found in the hypothalamus, limbic system, pituitary, and gut. Older work characterized DSIP as a sleep-modulating peptide rather than a sedative, with a U-shaped activity curve where small doses or short infusions produced the strongest effect.
Key research findings
- 01
DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in the 1970s (work associated with Monnier and Schoenenberger) based on its association with delta-wave (slow-wave) sleep states in rabbits.
- 02
Subsequent attempts to reproduce robust sleep-promoting effects have been inconsistent across laboratories (animal model / human study, mixed).
- 03
Research has examined DSIP in relation to stress responses, the hypothalamic-pituitary-adrenal (HPA) axis, and circadian/neuroendocrine signaling (animal model / in vitro).
- 04
A specific endogenous receptor and a clearly defined mechanism for DSIP have not been firmly established, and findings have been difficult to replicate (in vitro / general).
Primary source: Human evidence: A handful of small placebo-controlled studies in chronic insomniacs from 1981-1987 reported modest improvements in total sleep time, sleep efficiency, and daytime function. Other studies in the same era found that improvement did not reach clinically significant differences from placebo. Sample sizes were 6-14 subjects. Withdrawal context: Russian and Eastern-European trials examined DSIP in opioid- and alcohol-withdrawal settings and reported reduced symptom severity in case-series and open-label work. These were not modern double-blind RCTs. Preclinical evidence: DSIP has been studied in rabbits, rats, mice, and cats; it crosses the blood-CSF barrier; it has been tied to delta-wave EEG activity, neurotransmitter changes, motor recovery in rat stroke models, and HPA-axis signaling. Evidence gap: There is no modern, large-sample, FDA-recognized RCT establishing DSIP's efficacy in any indication. The PCAC review scheduled for July 2026 is the next formal regulatory review point.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
May promote deeper, more restorative slow-wave sleep and improve subjective sleep quality[3][5].
Research suggests potential stress-protective and anxiolytic-like effects[4][11].
Some studies indicate DSIP does not induce pharmacological tolerance with continued use[2].
Protocol Reference
Protocol reference
Commonly cited research range: 100–300 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Lower research planning
100-200 mcg
Higher research planning
200-300 mcg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Lower research planning | 100-200 mcg | 2–4 units (0.02–0.04 mL) |
| Higher research planning | 200-300 mcg | 4–6 units (0.04–0.06 mL) |
Titration protocol
- Lower research planningStart100-200 mcg SubQ
Single evening dose 1-3 hours before intended sleep.
- Higher research planningMaintenance200-300 mcg SubQ
Single evening dose 1-3 hours before intended sleep; 300 mcg is the top of the described range. Review points: end of week 1 (short 5-7 night course), week 4 (standard cycle), week 6 (extended 6-8 week cycle).
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Inspect the vial — check the label, lot number, fill, and powder appearance before reconstitution.
- 02🧴Wipe both stoppers — use a fresh alcohol swab on the BAC water vial stopper and the DSIP vial stopper.
- 03💉Draw 1 mL bacteriostatic water into a sterile syringe — this 5 mg vial yields 5 mg/mL.
- 04💧Add slowly down the side — inject the BAC water slowly down the inner wall of the DSIP vial. Do not spray it directly onto the powder.
- 05🔄Swirl gently — roll or swirl the vial gently until the powder fully dissolves. Do not shake.
- 06🏷️Label and date — mark the reconstitution date and concentration on the vial.
- 07❄️Refrigerate — store reconstituted DSIP at 35.6–46.4 °F (2–8 °C) and use within typical research peptide stability windows. Do not freeze.
- 08💉Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure [8] .
Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~4 weeks and avoid freeze–thaw [9] .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Research has examined effects on sleep regulation, stress-hormone modulation, and antioxidant pathways, largely in animal models and small early studies.
Human evidence: A handful of small placebo-controlled studies in chronic insomniacs from 1981-1987 reported modest improvements in total sleep time, sleep efficiency, and daytime function. Other studies in the same era found that improvement did not reach clinically significant differences from placebo. Sample sizes were 6-14 subjects. Withdrawal context: Russian and Eastern-European trials examined DSIP in opioid- and alcohol-withdrawal settings and reported reduced symptom severity in case-series and open-label work. These were not modern double-blind RCTs. Preclinical evidence: DSIP has been studied in rabbits, rats, mice, and cats; it crosses the blood-CSF barrier; it has been tied to delta-wave EEG activity, neurotransmitter changes, motor recovery in rat stroke models, and HPA-axis signaling. Evidence gap: There is no modern, large-sample, FDA-recognized RCT establishing DSIP's efficacy in any indication. The PCAC review scheduled for July 2026 is the next formal regulatory review point.
- 01DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in the 1970s (work associated with Monnier and Schoenenberger) based on its association with delta-wave (slow-wave) sleep states in rabbits.
- 02Subsequent attempts to reproduce robust sleep-promoting effects have been inconsistent across laboratories (animal model / human study, mixed).
- 03Research has examined DSIP in relation to stress responses, the hypothalamic-pituitary-adrenal (HPA) axis, and circadian/neuroendocrine signaling (animal model / in vitro).
- 04A specific endogenous receptor and a clearly defined mechanism for DSIP have not been firmly established, and findings have been difficult to replicate (in vitro / general).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to DSIP.
- 01Schoenenberger GA, Monnier M (1977) — Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA View Sourceet al. (1977)
- 02European Journal of Anaesthesiology (2001) — Delta sleep-inducing peptide: editorial review of mechanisms and clinical context View Sourceet al. (2001)
- 03Schneider-Helmert D, Schoenenberger GA (1983) — Effects of DSIP in man: multifunctional psychophysiological properties. Neuropsychobiology View Sourceet al. (1983)
- 04Sudakov KV et al. (2004) — Delta-sleep-inducing peptide sequelae: stress protective effect. Ann N Y Acad Sci View Sourceet al. (2004)
- 05Schneider-Helmert D (1981) — Acute and delayed effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol View Sourceet al. (1981)
- 06Graf MV, Kastin AJ (1984) — Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev View Sourceet al. (1984)
- 07Iyer KS et al. (1988) — Sleep-inducing effect of low doses of DSIP in rats. Indian J Exp Biol View Sourceet al. (1988)
- 08Manning MC et al. (2010) — Stability of protein pharmaceuticals: an update. Pharm Res View Sourceet al. (2010)
- 09Wang W (2000) — Lyophilization and development of solid protein pharmaceuticals. Int J Pharm View Sourceet al. (2000)
- 10Yehuda S, Carasso RL (1988) — DSIP: brain mechanisms and function. Int J Neurosci View Sourceet al. (1988)
- 11Khvatova EM et al. (2003) — Delta sleep-inducing peptide: effect on oxidative stress in brain during different models. Biull Eksp Biol Med View Sourceet al. (2003)
- 12CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) View Source
- 13NCBI Bookshelf — Medication Administration: Subcutaneous Injections (Open RN Nursing Skills) View Source
- 14Pure Lab Peptides — DSIP (5 mg) product page (quality and batch documentation) View Source
Observed Effects
Observed effects in cited research
Reported and Theoretical Risks
- Mild transient headache or nausea reported in some early human studies.
- Possible morning sluggishness or vivid dream effects described in research write-ups.
- Theoretical immunogenicity flagged by FDA in the Category 2 listing.
- Possible interaction with HPA-axis hormones; not characterized in modern trials.
- Quality-control risk for any research-use peptide (purity, contamination, mislabeling).
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Human evidence is limited to early or small studies. Consult a licensed healthcare professional for any clinical decisions.
- Pregnancy and lactation: not studied; should be avoided.
- Children and adolescents: no human pediatric data.
- Untreated obstructive sleep apnea: any sleep-modulating compound deserves clinical oversight.
- Active substance dependence: published trials in opioid- and alcohol-withdrawal contexts were small and used clinical settings, not self-directed protocols.
- Adrenal or thyroid disease: DSIP can interact with HPA-axis signaling; clinical oversight is warranted.
- Anyone on sedating medications: combined effects are not well characterized.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| DSIPthis | A naturally occurring nonapeptide studied for influence on sleep architecture and hypothalamic-pituitary-adrenal (stress-axis) modulation; its precise receptor targets remain incompletely characterized. | subcutaneous | Investigational / RUO |
| PE-22-28 | A synthetic heptapeptide (GVSWGLR) derived from the sortilin propeptide that acts as a selective antagonist of TREK-1 potassium channels, a mechanism studied for mood regulation and neuroplasticity. | subcutaneous | Investigational / RUO |
| Pinealon | A synthetic tripeptide bioregulator (Glu-Asp-Arg) studied for cell-penetrating, gene-regulatory activity in neural tissue, with proposed antioxidant and neuroprotective effects. | subcutaneous | Investigational / RUO |
| Selank | Modulates GABA and serotonin systems. Increases BDNF. Provides anxiolytic effects without sedation or cognitive impairment. | nasal, subcutaneous | Investigational / RUO |
| Semax | Increases BDNF expression, enhances dopamine and serotonin metabolism. Provides neuroprotection and cognitive enhancement. | nasal, subcutaneous | Investigational / RUO |
| Epitalon (Epithalon) | A synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied for activation of telomerase and modulation of pineal/melatonin and circadian pathways, of interest in geroprotection research. | subcutaneous | Investigational / RUO |
| FOXO4-DRI | A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells, releasing p53 to selectively induce apoptosis of senescent cells (a senolytic mechanism). | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide first isolated in 1974 from the cerebral venous blood of sleeping rabbits. It has been studied for sleep, opioid and alcohol withdrawal, stress, and pain modulation. The FDA refers to it as Emideltide.
No. DSIP is not FDA-approved for any human indication. As of September 2023 it is on the FDA Category 2 list of bulk drug substances that may not be compounded, and a PCAC review is scheduled for July 2026 under the name Emideltide.
Two patterns appear in the literature. Older human trials used 25 nmol/kg intravenously for short 4-7 night courses. Community research planning today is mostly subcutaneous in the 100-300 mcg range. This is not a dosing recommendation.
A common research approach is to add 2.0 mL of bacteriostatic water to a 10 mg vial, which gives a 5 mg/mL working concentration. On a U-100 insulin syringe, 0.02 mL (2 units) is about 100 mcg, 0.04 mL (4 units) is about 200 mcg, and 0.06 mL (6 units) is about 300 mcg. For other vial sizes, use the PepPal reconstitution calculator .
Most research write-ups describe a single evening subcutaneous research-use dose 1-3 hours before intended sleep. Older human studies used short intravenous courses given in clinical settings.
Older trials and reviews report mild transient headache, nausea, and occasional dizziness. The FDA flagged theoretical immunogenicity risk in its Category 2 listing. Long-term safety has not been formally established.
Melatonin is an OTC hormone supplement that mainly shifts sleep timing through the circadian system. DSIP is a research-use peptide that has been described as modulating sleep architecture (especially slow-wave sleep) rather than acting as a sedative. They work through different pathways and are not interchangeable.
No. This page is an educational research reference. DSIP is not FDA-approved and is currently on the FDA Category 2 do-not-compound list. Talk to a qualified clinician before any peptide use.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.